Short-term treatment with parecoxib for complex regional pain syndrome: A randomized, placebo-controlled double-blind trial

Pain Physician

Volumn 17, Issue 2, 2014, Pages 127-137

  Breuer, Anna J ^a   Mainka, Tina ^a   Hansel, Nora ^a   Maier, Christoph ^a   Krumova, Elena K ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Complex regional pain syndrome; Inflammation; Parecoxib; Pressure hyperalgesia; Pressure pain threshold; Quantitative sensory testing

Indexed keywords

BUPRENORPHINE; NALOXONE; PARECOXIB; PLACEBO; TILIDINE;

ADULT; ANALGESIA; ARTICLE; CLINICAL ARTICLE; COMPLEX REGIONAL PAIN SYNDROME; DOUBLE BLIND PROCEDURE; EDEMA; FEMALE; HEAT PAIN THRESHOLD; HUMAN; HYPERALGESIA; MALE; MECHANICAL PAIN THRESHOLD; MOOD CHANGE; PAIN; PAIN THRESHOLD; PRESSURE PAIN THRESHOLD; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; COMPLEX REGIONAL PAIN SYNDROMES; CYCLOOXYGENASE 2 INHIBITORS; DOUBLE-BLIND METHOD; EDEMA; FEMALE; HUMANS; HYPERALGESIA; ISOXAZOLES; MALE; MIDDLE AGED; PAIN MEASUREMENT; QUESTIONNAIRES; SENSORY THRESHOLDS; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 84897867142     PISSN: 15333159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Harden RN, Oaklander AL, Burton AW, Perez RS, Richardson K, Swan M, Barthel J, Costa B, Graciosa JR, Bruehl S; Reflex Sympathetic Dystrophy Syndrome Association. Complex regional pain syndrome: Practical diagnostic and treatment guidelines, 4th edition. Pain Med 2013; 14:180-229
2. Baron R. Mechanisms of disease: Neuropathic pain - a clinical perspective. Nat Clin Pract Neurol 2006; 2:95-106
3. Birklein F, Schmelz M. Neuropeptides, neurogenic inflammation and complex regional pain syndrome (CRPS). Neurosci Lett 2008; 437:199-202
4. Gierthmühlen J, Maier C, Baron R, Tölle T, Treede RD, Birbaumer N, Huge V, Koroschetz J, Krumova E, Lauchart M, Maihöfner C, Richter H, Westermann A. Sensory signs in complex regional pain syndrome and peripheral nerve injury. Pain 2012; 153:765-774
5. Greffrath W, Baumgärtner U, Treede RD. Peripheral and central components of habituation of heat pain perception and evoked potentials in humans. Pain 2007; 132:301-311
6. Woolf CJ. Central sensitization: Implications for the diagnosis and treatment of pain. Pain 2011; 152:S2-S15
7. Bianchi C, Rossi S, Turi S, Brambilla A, Felisari G, Mascheri D. Long-term functional outcome measures in corticosteroid- treated complex regional pain syndrome. Eura Medicophys 2006; 42:103-111
8. Alexander GM, van Rijn MA, van Hilten JJ, Perreault MJ, Schwartzman RJ. Changes in cerebrospinal fluid levels of proinflammatory cytokines in CRPS. Pain 2005; 116:213-219
9. Maihöfner C, Handwerker HO, Neundörfer B, Birklein F. Mechanical hyperalgesia in complex regional pain syndrome: A role for TNF-alpha? Neurology 2005; 65:311-313
10. Uceyler N, Eberle T, Rolke R, Birklein F, Sommer C. Differential expression patterns of cytokines in complex regional pain syndrome. Pain 2007; 132:195-205
11. Groeneweg JG, Huygen FJ, Heijmans- Antonissen C, Niehof S, Zijlstra FJ. Increased endothelin-1 and diminished nitric oxide levels in blister fluids of patients with intermediate cold type complex regional pain syndrome type 1. BMC Musculoskelet Disord 2006; 7:91
12. Heijmans-Antonissen C, Wesseldijk F, Munnikes RJ, Huygen FJ, van der Meijden P, Hop WC, Hooijkaas H, Zijlstra FJ. Multiplex bead array assay for detection of 25 soluble cytokines in blister fluid of patients with complex regional pain syndrome type 1. Mediators Inflamm 2006; 2006:28398
13. Lenz M, Uçeyler N, Frettlöh J, Höffken O, Krumova EK, Lissek S, Reinersmann A, Sommer C, Stude P, Waaga-Gasser AM, Tegenthoff M, Maier C. Local cytokine changes in complex regional pain syndrome type I (CRPS I) resolve after 6 months. Pain 2013; 154:2142-2149
14. Durrenberger PF, Facer P, Casula MA, Yiangou Y, Gray RA, Chessell IP, Day NC, Collins SD, Bingham S, Wilson AW, Elliot D, Birch R, Anand P. Prostanoid receptor EP1 and Cox-2 in injured human nerves and a rat model of nerve injury: a time-course study. BMC Neurol 2006; 6:1
15. Ma W, Quirion R. Targeting invading macrophage-derived PGE2, IL-6 and calcitonin gene-related peptide in injured nerve to treat neuropathic pain. Expert Opin Ther Targets 2006; 10:533-546
16. Zanella JM, Burright EN, Hildebrand K, Hobot C, Cox M, Christoferson L, McKay WF. Effect of etanercept, a tumor necrosis factor-alpha inhibitor, on neuropathic pain in the rat chronic constriction injury model. Spine 2008; 33:227-234
17. Claudino RF, Kassuya CA, Ferreira J, Calixto JB. Pharmacological and molecular characterization of the mechanisms involved in prostaglandin E2-induced mouse paw edema. J Pharmacol Exp Ther 2006; 318:611-618
18. Williams TJ, Morley J. Prostaglandins as potentiators of increased vascular permeability in inflammation. Nature 1973; 246:215-217
19. Dorris SL, Peebles RS Jr. PGI2 as a regulator of inflammatory diseases. Mediators Inflamm 2012; 2012:926968
20. Bernateck M, Rolke R, Birklein F, Treede RD, Fink M, Karst M. Successful intravenous regional block with low-dose tumor necrosis factor-alpha antibody infliximab for treatment of complex regional pain syndrome 1. Anesth Analg 2007; 105:1148-1151
21. Zyluk A, Puchalski P. Treatment of early complex regional pain syndrome type 1 by a combination of mannitol and dexamethasone. J Hand Surg Eur 2007; 33:130-136
22. Simpson DM, Schifitto G, Clifford DB, Murphy TK, Durso-De Cruz E, Glue P, Whalen E, Emir B, Scott GN, Freeman R; 1066 HIV Neuropathy Study Group. Pregabalin for painful HIV neuropathy: A randomized, double-blind, placebo- controlled trial. Neurology 2010; 74:413-420
23. Wasner G, Kleinert A, Binder A, Schattschneider J, Baron R. Postherpetic neuralgia: Topical lidocaine is effective in nociceptor-deprived skin. J Neurol 2005; 252:677-686
24. Attal N, Bouhassira D, Baron R, Dostrovsky J, Dworkin RH, Finnerup N, Gourlay G, Haanpaa M, Raja S, Rice AS, Simpson D, Treede RD. Assessing symptom profiles in neuropathic pain clinical trials: Can it improve outcome? Eur J Pain 2011; 15:441-443
25. Harden RN, Bruehl S, Perez RS, Birklein F, Marinus J, Maihofner C, Lubenow T, Buvanendran A, Mackey S, Graciosa J, Mogilevski M, Ramsden C, Chont M, Vatine JJ. Validation of proposed diagnostic criteria (the "Budapest Criteria") for complex regional pain syndrome. Pain 2010; 150:268-274
26. Lee GW, Weeks PM. The role of bone scintigraphy in diagnosing reflex sympathetic dystrophy. J Hand Surg (Am) 1995; 20A:458-463
27. Wüppenhorst N, Maier C, Frettlöh J, Pennekamp W, Nicolas V. Sensitivity and specificity of 3-phase bone scintigraphy in the diagnosis of complex regional pain syndrome of the upper extremity. Clin J Pain 2010; 26:182-189
28. Zyluk A. The usefulness of quantitative evaluation of three-phase scintigraphy in the diagnosis of post-traumatic reflex sympathetic dystrophy. Hand Surg (Br) 1999; 24:16-21
29. Magerl W, Krumova EK, Baron R, Tölle T, Treede RD, Maier C. Reference data for quantitative sensory testing (QST): Refined stratification for age and a novel method for statistical comparison of group data. Pain 2010; 151:598-605
30. Rolke R, Baron R, Maier C, Tölle TR, Treede RD, Beyer A, Binder A, Birbaumer N, Birklein F, Bötefür IC, Braune S, Flor H, Huge V, Klug R, Landwehrmeyer GB, Magerl W, Maihöfner C, Rolko C, Schaub C, Scherens A, Sprenger T, Valet M, Wasserka B. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): Standardized protocol and reference values. Pain 2006; 123:231-243. Erratum in: Pain 2006; 125:197
31. Gierse JK, Zhan Y, Hood WF, Walker MC, Trigg JS, Maziasz TJ, Koboldt CM, Muhammad JL, Zweifel BS, Masferrer JL, Isakson PC, Seibert K. Valdecoxib: Assessment of cyclooxygenase-2 potency and selectivity. J Pharmacol Exp Ther 2005; 312:1206-1212
32. Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Stegeman RA, Pak JY, Gildehaus D, Miyashiro JM, Penning TD, Seibert K, Isakson PC, Stallings WC. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996; 384:644-648
33. Abdulla S, Eckhardt R, Netter U, Abdulla W. Randomized, double-blind, placebocontrolled study to assess the efficacy of nonopioid analgesics on pain following arthroscopic knee surgery. Pain Res Treat 2012; 2012:305821
34. Amornyotin S, Chalayonnawin W, Kongphlay S. A randomized controlled trial of preprocedure administration of parecoxib for therapeutic endoscopic retrograde cholangiopancreatography. J Pain Res 2012; 5:251-256
35. Lloyd R, Derry S, Moore RA, McQuay HJ. Intravenous or intramuscular parecoxib for acute postoperative pain in adults. Cochrane Database Syst Rev 2009; CD004771
36. Glina S, Damiao R, Afif-Abdo J, Santa Maria CF, Novoa R, Cairoli CE, Wajsbrot D, Araya G. Efficacy and safety of parecoxib in the treatment of acute renal colic: A randomized clinical trial. Int Braz J Urol 2011; 37:697-705
37. Jean YH, Wen ZH, Chang YC, Hsieh SP, Tang CC, Wang YH, Wong CS. Intra-articular injection of the cyclooxygenase-2 inhibitor parecoxib attenuates osteoarthritis progression in anterior cruciate ligament-transected knee in rats: Role of excitatory amino acids. Osteoarthritis Cartilage 2007; 15:638-645
38. Moskowitz RW, Sunshine A, Hooper M, Olson NZ, Cawkwell GD. An analgesic model for assessment of acute pain response in osteoarthritis of the knee. Osteoarthritis Cartilage 2006; 14:1111-1118
39. Frade LC, Lauretti GR, Lima IC, Pereira NL. The antinociceptive effect of local or systemic parecoxib combined with lidocaine/ clonidine intravenous regional analgesia for complex regional pain syndrome type I in the arm. Anesth Analg 2005;101:807-811
40. Herrmann-Lingen C, Buss U, Snaith RP. Hospital Anxiety and Depression Scale - German Version (HADS-D) (3. updated and a new standardized edition). Manual. Hans Huber, Bern, 2011
41. Kool J, Reubsaet L, Wesseldijk F, Maravilha RT, Pinkse MW, D'Santos CS, van Hilten JJ, Zijlstra FJ, Heck AJ. Suction blister fluid as potential body fluid for biomarker proteins. Proteomics 2007; 7:3638-3650
42. Leis S, Weber M, Isselmann A, Schmelz M, Birklein F. Substance-P-induced protein extravasation is bilaterally increased in complex regional pain syndrome. Exp Neurol 2003; 183:197-204
43. Leis S, Weber M, Schmelz M, Birklein F. Facilitated neurogenic inflammation in unaffected limbs of patients with com plex regional pain syndrome. Neurosci Lett 2004; 359:163-166
44. Weber M, Birklein F, Neundörfer B, Schmelz M. Facilitated neurogenic inflammation in complex regional pain syndrome. Pain 2001; 91:251-257
45. Kohr D, Tschernatsch M, Schmitz K, Singh P, Kaps M, Schäfer KH, Diener M, Mathies J, Matz O, Kummer W, Maihöfner C, Fritz T, Birklein F, Blaes F. Autoantibodies in complex regional pain syndrome bind to a differentiation-dependent neuronal surface autoantigen. Pain 2009; 143:246-251
46. Kohr D, Singh P, Tschernatsch M, Kaps M, Pouokam E, Diener M, Kummer W, Birklein F, Vincent A, Goebel A, Wallukat G, Blaes F. Autoimmunity against the β2 adrenergic receptor and muscarinic-2 receptor in complex regional pain syndrome. Pain 2011; 152:2690-2700
47. Kilo S, Schmelz M, Koltzenburg M, Handwerker HO. Different patterns of hyperalgesia induced by experimental inflammation in human skin. Brain 1994; 117:385-396
48. Jänig W, Baron R. Complex regional pain syndrome is a disease of the central nervous system. Clin Auton Res 2002; 12:150-164
49. Koppert W, Wehrfritz A, Körber N, Sittl R, Albrecht S, Schüttler J, Schmelz M. The cyclooxygenase isozyme inhibitors parecoxib and paracetamol reduce central hyperalgesia in humans. Pain 2004; 108:148-153
50. Ma W, Du W, Eisenach JC. Role for both spinal cord COX-1 and COX-2 in maintenance of mechanical hypersensitivity following peripheral nerve injury. Brain Res 2002; 937:94-99
51. Samad TA, Moore KA, Sapirstein A, Billet S, Allchorne A, Poole S, Bonventre JV, Woolf CJ. Interleukin-1beta-mediated induction of COX-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 2001; 410:471-475
52. Schäfers M, Marziniak M, Sorkin LS, Yaksh TL, Sommer C. Cyclooxygenase inhibition in nerve-injury- and TNF-induced hyperalgesia in the rat. Exp Neurol 2004; 185:160-168
53. Kirillova I, Rausch VH, Tode J, Baron R, Jänig W. Mechano- and thermosensitivity of injured muscle afferents. J Neurophysiol 2011; 105:2058-2073
54. Pleger B, Tegenthoff M, Ragert P, Förster A-F, Dinse H R, Schwenkreis P, Nicolas V, Maier C. Sensorimotor returning in complex regional pain syndrome parallels pain reduction. Ann Neurol 2005; 57:425-429
55. Carr FA, Healy KM, Villavicencio AT, Nelson EL, Mason A, Burneikiene S, Hernández TD. Effect on clinical outcomes of patient pain expectancies and preoperative Mental Component Summary scores from the 36-Item Short Form Health Survey following anterior cervical discectomy and fusion. J Neurosurg Spine 2011; 15:486-490
56. Morton DL, El-Deredy W, Watson A, Jones AK. Placebo analgesia as a case of a cognitive style driven by prior expectation. Brain Res 2010; 1359:137-141
57. Petersen GL, Finnerup NB, Nørskov KN, Grosen K, Pilegaard HK, Benedetti F, Price DD, Jensen TS, Vase L. Placebo manipulations reduce hyperalgesia in neuropathic pain. Pain 2012; 153:1292-1300
58. Price D, Finnis D, Beneddetti F. A comprehensive review of the placebo effect: Recent advances and current thought. Annu Rev Psychol 2008; 59:565-590
59. Vadalouca A, Moka E, Chatzidimitriou A, Siafaka I, Sikioti P, Argyra E. A randomized, double-blind, placebo-controlled study of preemptively administered intravenous parecoxib: effect on anxiety levels and procedural pain during epidural catheter placement for surgical operations or for chronic pain therapy. Pain Pract 2009; 9:181-194.